This trial is active, not recruiting.

Condition asteroid hyalosis
Treatment c-kad ophthalmic solution
Phase phase 2
Sponsor Chakshu Research, Inc.
Start date July 2008
End date October 2009
Trial size 20 participants
Trial identifier NCT00825942, PCK-0108


To determine the safety and initial efficacy of C-KAD ophthalmic solution in patients with asteroid hyalosis

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
c-kad ophthalmic solution
4 drops applied daily for 180 days

Primary Outcomes

Reduction in the number of asteroid bodies
time frame: 180

Eligibility Criteria

Male or female participants from 21 years up to 90 years old.

Inclusion Criteria: - Presence of asteroid hyalosis Exclusion Criteria: - Active ocular infection - Glaucoma - Ocular hypertension - Ocular inflammatory disorders

Additional Information

Official title An Open-Label Study of the Effect of C-KAD Ophthalmic Solution on Asteroid Hyalosis
Trial information was received from ClinicalTrials.gov and was last updated in April 2009.
Information provided to ClinicalTrials.gov by Chakshu Research, Inc..